Ozempic vs Wegovy: Same Molecule, Different Approval, Different Bill

Ozempic and Wegovy are the same molecule, made by the same company, and people use both terms almost interchangeably in casual conversation. That's the source of most of the confusion — because on paper, the FDA treats them as two different drugs with two different jobs, and that difference is exactly what determines whether your insurance pays for one, the other, neither, or both.

Same drug, different approved use

Both Ozempic and Wegovy contain semaglutide. The difference is what each one is FDA-approved to treat. Ozempic's current label is specific: it's indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease¹. Nowhere in that label does it say weight loss or chronic weight management — Ozempic is not FDA-approved for that use. Wegovy, by contrast, is the same active ingredient formulated and approved specifically for chronic weight management, at a higher maintenance dose (2.4 mg vs Ozempic's top labeled dose of 2 mg), and its pivotal trial measured weight loss as the primary outcome, producing roughly 15% mean body weight reduction over 68 weeks².

Why Ozempic gets prescribed for weight loss anyway

If Ozempic isn't approved for weight loss, why does almost everyone know it as "the weight loss drug"? Because physicians can legally prescribe an FDA-approved drug off-label for a use outside its labeled indication, and a large-scale study of semaglutide prescribing in Denmark from 2018 through 2023 documented exactly this pattern at national scale — semaglutide use expanded rapidly, driven substantially by off-label prescribing beyond the diabetes population the drug was approved to treat³. The same dynamic has played out in the U.S.: Ozempic became a cultural shorthand for GLP-1 weight loss specifically because it was the first widely available, widely advertised semaglutide product, even though the drug carrying the weight-management label is Wegovy.

The part that actually matters for your wallet

This is where the distinction stops being academic. Insurance plans generally evaluate a prescription against the drug's FDA-approved indication. A plan that covers diabetes medications may pay for Ozempic if you have type 2 diabetes — that's squarely on-label. The same plan may flatly exclude Wegovy, because most commercial and government plans still treat anti-obesity medications as a distinct, frequently excluded category regardless of medical necessity — see our breakdown of how GLP-1 prior authorization actually works and the specific federal rules that govern Medicare and Medicaid coverage for a fuller picture of why that exclusion exists. In practice, this means some patients without diabetes have historically sought an off-label Ozempic prescription specifically because it was more likely to clear a formulary built around diabetes coverage than a same-molecule product explicitly labeled for weight loss — a coverage quirk, not a clinical one, and one insurers have been tightening as scrutiny of off-label GLP-1 prescribing has increased.

Dosing and price aren't identical either

Because Wegovy's maintenance dose (2.4 mg) is higher than Ozempic's top labeled dose (2 mg), the two aren't simply interchangeable vials — a prescriber moving a patient from one to the other has to think about the dose ceiling, not just the brand name, and should follow the labeled titration schedule for whichever product is prescribed. On price, brand Ozempic and brand Wegovy are both expensive without coverage, and manufacturer list price is not the number most cash-pay patients actually see — see what a GLP-1 costs without insurance for the real cash-pay math on both. Compounded semaglutide, sold under neither brand name, sidesteps this Ozempic-vs-Wegovy branding question entirely, which is one reason it has become the default cash-pay route — see is compounded semaglutide legit and safe before assuming that's automatically the cheaper or simpler path for you.

The one-sentence version

Ozempic and Wegovy are the same drug, semaglutide, sold under two names for two FDA-approved purposes — diabetes management and chronic weight management, respectively — and that labeling difference, not any difference in the molecule, is what determines your insurance coverage, your dose ceiling, and often your actual out-of-pocket bill. If your goal is weight loss, price out the on-label route (Wegovy pricing) against a verified compounded provider before assuming the off-label route is the practical shortcut it looks like — a plan that denies Wegovy will often deny an off-label Ozempic weight-loss claim just as fast once it's flagged. The sourcing behind this comparison is indexed in our research library. Not medical advice — see our medical disclaimer and talk to your prescriber about which approved use actually applies to you.